{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T21:35:23Z","timestamp":1790804123821,"version":"4.1.0"},"reference-count":55,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2008,7,11]],"date-time":"2008-07-11T00:00:00Z","timestamp":1215734400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Brit J Clinical Pharma"],"published-print":{"date-parts":[[2008,11]]},"abstract":"<jats:p>Adalimumab is a biological agent, one of the tumour necrosis factor\u2010alpha inhibitors. Pivotal studies evaluating its efficacy in plaque psoriasis (CHAMPION, REVEAL) and psoriatic arthritis (PsA) (ADEPT) were carried out in recent years. Adalimumab proved highly effective in psoriasis patients and in PsA patients previously unresponsive to nonsteroidal anti\u2010inflammatory drugs. Results of smaller studies suggest therapy with the drug may be successful in psoriasis resistant to other biologics and PsA unresponsive to disease\u2010modifying antirheumatic drugs. Adalimumab has also been shown to improve patients' quality of life significantly. Although they should be further extended as far as dermatological conditions are concerned, available data indicate adalimumab is safe and well tolerated. Numerous case reports featuring its off\u2010label use suggest the drug could be helpful in treating hidradenitis suppurativa, pyoderma gangrenosum, Sweet's syndrome, cutaneous sarcoidosis, pemphigus, systemic vasculitides, multicentric reticulohistiocytosis and stomatitis.<\/jats:p>","DOI":"10.1111\/j.1365-2125.2008.03263.x","type":"journal-article","created":{"date-parts":[[2008,7,11]],"date-time":"2008-07-11T10:28:38Z","timestamp":1215772118000},"page":"618-625","source":"Crossref","is-referenced-by-count":42,"title":["Adalimumab in dermatology"],"prefix":"10.1111","volume":"66","author":[{"given":"Pawel","family":"Traczewski","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lidia","family":"Rudnicka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2008,10,28]]},"reference":[{"key":"e_1_2_9_2_2","doi-asserted-by":"publisher","DOI":"10.1007\/3-7643-7438-1_3"},{"key":"e_1_2_9_3_2","unstructured":"European Medicines Agency.Summary of product characteristics. Available athttp:\/\/www.emea.europa.eu\/humandocs\/PDFs\/EPAR\/humira\/H\u2010481\u2010PI\u2010en.pdf(last accessed: 3 April 2008)."},{"key":"e_1_2_9_4_2","unstructured":"Abbott.Full prescribing information. 2008 February. Available athttp:\/\/www.fda.gov\/cder\/foi\/label\/2008\/125057s114lbl.pdf(last accessed: 3 April 2008)."},{"key":"e_1_2_9_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(07)61128-3"},{"key":"e_1_2_9_6_2","doi-asserted-by":"publisher","DOI":"10.1007\/3-7643-7438-1_1"},{"key":"e_1_2_9_7_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1529-8019.2007.00138.x"},{"key":"e_1_2_9_8_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2004.06105.x"},{"key":"e_1_2_9_9_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2005.06582.x"},{"key":"e_1_2_9_10_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2007.08315.x"},{"key":"e_1_2_9_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2007.09.010"},{"key":"e_1_2_9_12_2","doi-asserted-by":"publisher","DOI":"10.1001\/archderm.139.12.1627"},{"key":"e_1_2_9_13_2","doi-asserted-by":"publisher","DOI":"10.1001\/archderm.139.6.719"},{"key":"e_1_2_9_14_2","doi-asserted-by":"publisher","DOI":"10.1001\/archderm.141.1.31"},{"key":"e_1_2_9_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(05)67566-6"},{"key":"e_1_2_9_16_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2006.12.003"},{"key":"e_1_2_9_17_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2230.2006.02288.x"},{"key":"e_1_2_9_18_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2007.08236.x"},{"key":"e_1_2_9_19_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2007.07817.x"},{"key":"e_1_2_9_20_2","doi-asserted-by":"publisher","DOI":"10.1080\/09546630601121060"},{"key":"e_1_2_9_21_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-200666110-00008"},{"key":"e_1_2_9_22_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1396-0296.2004.04038.x"},{"key":"e_1_2_9_23_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11926-006-0064-9"},{"key":"e_1_2_9_24_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.21306"},{"key":"e_1_2_9_25_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.22379"},{"key":"e_1_2_9_26_2","first-page":"1040","article-title":"Safety and efficacy of adalimumab treatment in patients with psoriatic arthritis who had failed disease modifying therapy","volume":"34","author":"Genovese MC","year":"2007","journal-title":"J Rheumatol"},{"key":"e_1_2_9_27_2","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2006.057901"},{"key":"e_1_2_9_28_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2006.07.019"},{"key":"e_1_2_9_29_2","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-540-33101-8_20"},{"key":"e_1_2_9_30_2","doi-asserted-by":"publisher","DOI":"10.1001\/archderm.142.9.1110"},{"key":"e_1_2_9_31_2","doi-asserted-by":"publisher","DOI":"10.1001\/archderm.143.3.306"},{"key":"e_1_2_9_32_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2007.08212.x"},{"key":"e_1_2_9_33_2","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1111\/j.1365-2133.2005.06467.x","article-title":"Systemic pyoderma responding to infliximab and adalimumab","volume":"152","author":"Hubbard VG","journal-title":"Br J Dermatol"},{"key":"e_1_2_9_34_2","first-page":"e8","article-title":"Adalimumab therapy for recalcitrant pyoderma gangrenosum","volume":"5","author":"Margaret AF","year":"2006","journal-title":"J Burns Wounds"},{"key":"e_1_2_9_35_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.rhu.0000147053.60795.46"},{"key":"e_1_2_9_36_2","doi-asserted-by":"publisher","DOI":"10.1001\/archderm.142.1.17"},{"key":"e_1_2_9_37_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2005.02.023"},{"key":"e_1_2_9_38_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-005-0037-9"},{"key":"e_1_2_9_39_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.eye.6702352"},{"key":"e_1_2_9_40_2","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2006.064279"},{"key":"e_1_2_9_41_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2005.02.051"},{"key":"e_1_2_9_42_2","first-page":"565","article-title":"Multicentric reticulohistiocytosis responding to tumor necrosis factor\u2010alpha inhibition in a renal transplant patient","volume":"32","author":"Shannon SE","year":"2005","journal-title":"J Rheumatol"},{"key":"e_1_2_9_43_2","first-page":"129","article-title":"Treatment of severe, recalcitrant major aphthous stomatitis with adalimumab","volume":"76","author":"Vujevich J","year":"2005","journal-title":"Cutis"},{"key":"e_1_2_9_44_2","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-540-29018-6_3"},{"key":"e_1_2_9_45_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(07)61129-5"},{"key":"e_1_2_9_46_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2008.02.039"},{"key":"e_1_2_9_47_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2008.02.040"},{"key":"e_1_2_9_48_2","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2005.043166"},{"key":"e_1_2_9_49_2","first-page":"411","article-title":"Injection site reactions in adalimumab rheumatoid arthritis (RA) pivotal clinical trials","volume":"62","author":"Wells AF","year":"2003","journal-title":"Ann Rheum Dis"},{"key":"e_1_2_9_50_2","doi-asserted-by":"publisher","DOI":"10.1007\/3-7643-7438-1_10"},{"key":"e_1_2_9_51_2","doi-asserted-by":"publisher","DOI":"10.1517\/14740338.4.4.637"},{"key":"e_1_2_9_52_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-4632.2004.02571.x"},{"key":"e_1_2_9_53_2","doi-asserted-by":"publisher","DOI":"10.1186\/ar1724"},{"key":"e_1_2_9_54_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-007-0789-5"},{"key":"e_1_2_9_55_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-005-0197-7"},{"key":"e_1_2_9_56_2","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2007.081513"}],"container-title":["British Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1365-2125.2008.03263.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1365-2125.2008.03263.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,16]],"date-time":"2023-10-16T11:14:37Z","timestamp":1697454877000},"score":1,"resource":{"primary":{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/10.1111\/j.1365-2125.2008.03263.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,10,28]]},"references-count":55,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2008,11]]}},"alternative-id":["10.1111\/j.1365-2125.2008.03263.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1365-2125.2008.03263.x","archive":["Portico"],"relation":{},"ISSN":["0306-5251","1365-2125"],"issn-type":[{"value":"0306-5251","type":"print"},{"value":"1365-2125","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,10,28]]}}}